Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BMP1 | P13497 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923393 | 0.82 | KDM4C (0.37) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL15479751 | 0.70 | BMP1 (0.39) | NPC1RAB9ABMP1CNR2MEN1 | |
| SCHEMBL4081854 | 0.69 | ICAM1 (0.40) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL15479746 | 0.69 | BMP1 (0.40) | NPC1RAB9ABMP1 | |
| SCHEMBL18704229 | 0.68 | KDM4C (0.37) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL15479740 | 0.67 | ALDH1A1 (0.37) | BMP1CNR2MEN1KMT2AGPR119 | |
| SCHEMBL12251792 | 0.66 | ALDH1A1 (0.42) | NPC1RAB9AL3MBTL1BMP1CNR2 | |
| SCHEMBL15677573 | 0.66 | HTT (0.34) | CNR2GPR84 | |
| SCHEMBL24006607 | 0.66 | KDM4C (0.41) | KDM4CNPC1RAB9AL3MBTL1MEN1 | |
| SCHEMBL3889222 | 0.66 | KDM4C (0.46) | KDM4CNPC1RAB9AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | KDM4C 737/4885NPC1 3905/4885RAB9A 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.